Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 381Breast Neoplasms 364Colorectal Neoplasms 238Stomach Neoplasms 218Carcinoma, Hepatocellular 155Lung Neoplasms 123Neoplasms 120Pancreatic Neoplasms 109Prostatic Neoplasms 100Neoplasm Metastasis 96Recurrence 95Rectal Neoplasms 95Ovarian Neoplasms 90Nasopharyngeal Carcinoma 88Esophageal Neoplasms 82Esophageal Squamous Cell Carcinoma 81Lymphoma, Large B-Cell, Diffuse 79Melanoma 75Small Cell Lung Carcinoma 71Uterine Cervical Neoplasms 70Lymphoma 70Leukemia, Myeloid, Acute 70Brain Neoplasms 69Sarcoma 68Head and Neck Neoplasms 68Squamous Cell Carcinoma of Head and Neck 67Multiple Myeloma 65Carcinoma, Renal Cell 63Triple Negative Breast Neoplasms 61Lymphoma, Non-Hodgkin 53

Interventions

afamelanotide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Xeroderma Pigmentosum × Clear all
NCT05370235 2023-09-21

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V

Clinuvel Pharmaceuticals Limited

Phase 2 Unknown
6 enrolled

Xeroderma Pigmentosum

NCT05159752 2023-06-18

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)

Clinuvel Pharmaceuticals Limited

Phase 2 Unknown
6 enrolled

Xeroderma Pigmentosum

Data powered by HemOnc (CC BY 4.0) Colophon âš¡